150 related articles for article (PubMed ID: 12010908)
1. Calcineurin in human heart hypertrophy.
Ritter O; Hack S; Schuh K; Röthlein N; Perrot A; Osterziel KJ; Schulte HD; Neyses L
Circulation; 2002 May; 105(19):2265-9. PubMed ID: 12010908
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.
Diedrichs H; Mei C; Frank KF; Boelck B; Schwinger RH
J Mol Med (Berl); 2004 Oct; 82(10):688-95. PubMed ID: 15322704
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
4. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin and beyond: cardiac hypertrophic signaling.
Molkentin JD
Circ Res; 2000 Oct; 87(9):731-8. PubMed ID: 11055975
[TBL] [Abstract][Full Text] [Related]
6. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Diedrichs H; Chi M; Boelck B; Mehlhorn U; Schwinger RH
Eur J Heart Fail; 2004 Jan; 6(1):3-9. PubMed ID: 15012912
[TBL] [Abstract][Full Text] [Related]
7. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
Molkentin JD; Lu JR; Antos CL; Markham B; Richardson J; Robbins J; Grant SR; Olson EN
Cell; 1998 Apr; 93(2):215-28. PubMed ID: 9568714
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
Dong DL; Chen C; Huo R; Wang N; Li Z; Tu YJ; Hu JT; Chu X; Huang W; Yang BF
Hypertension; 2010 Apr; 55(4):946-52. PubMed ID: 20177001
[TBL] [Abstract][Full Text] [Related]
9. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
11. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
Passier R; Zeng H; Frey N; Naya FJ; Nicol RL; McKinsey TA; Overbeek P; Richardson JA; Grant SR; Olson EN
J Clin Invest; 2000 May; 105(10):1395-406. PubMed ID: 10811847
[TBL] [Abstract][Full Text] [Related]
12. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.
Kuwahara K; Wang Y; McAnally J; Richardson JA; Bassel-Duby R; Hill JA; Olson EN
J Clin Invest; 2006 Dec; 116(12):3114-26. PubMed ID: 17099778
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
[TBL] [Abstract][Full Text] [Related]
15. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
16. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
Musarò A; McCullagh KJ; Naya FJ; Olson EN; Rosenthal N
Nature; 1999 Aug; 400(6744):581-5. PubMed ID: 10448862
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.
Wilkins BJ; De Windt LJ; Bueno OF; Braz JC; Glascock BJ; Kimball TF; Molkentin JD
Mol Cell Biol; 2002 Nov; 22(21):7603-13. PubMed ID: 12370307
[TBL] [Abstract][Full Text] [Related]
18. Matching of calcineurin activity to upstream effectors is critical for skeletal muscle fiber growth.
Dunn SE; Chin ER; Michel RN
J Cell Biol; 2000 Oct; 151(3):663-72. PubMed ID: 11062266
[TBL] [Abstract][Full Text] [Related]
19. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.
Antos CL; McKinsey TA; Frey N; Kutschke W; McAnally J; Shelton JM; Richardson JA; Hill JA; Olson EN
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):907-12. PubMed ID: 11782539
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.
Taigen T; De Windt LJ; Lim HW; Molkentin JD
Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1196-201. PubMed ID: 10655507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
